Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting

Molecular Immunology

Volumn 50, Issue 4, 2012, Pages 200-209

  Singer, Josef ^a   Weichselbaumer, Marlene ^a,b   Stockner, Thomas ^c   Mechtcheriakova, Diana ^a   Sobanov, Yury ^a   Bajna, Erika ^a   Wrba, Friedrich ^c   Horvat, Reinhard ^c   Thalhammer, Johann G ^b   Willmann, Michael ^b   Jensen Jarolim, Erika ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Canine; Comparative oncology; ErbB 1; ErbB 2; Human

Indexed keywords

AMINO ACID; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; TRASTUZUMAB; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BREAST CANCER; CANIS LUPUS FAMILIARIS; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG BINDING; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL SEPARATION; CELL SURVIVAL; DOGS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 84858330284     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.01.002     Document Type: Article

References (55)

1. Ahern T.E., Bird R.C., Bird A.E., Wolfe LG Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am. J. Vet. Res. 1996, 57(5):693-696.
2. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 1990, 215(3):403-410. doi:10.1006/jmbi.1990.9999 S0022-2836(05)80360-2 [pii].
3. Banerjee S., Flores-Rozas H. Monoclonal antibodies for targeted therapy in colorectal cancer. Cancer Biol Ther 2010, 9(8):563-571. doi:11403 [pii].
4. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., Liao J., Riviere I., Sadelain M., Hohenhaus A.E., Gregor P., Houghton A.N., Perales M.A., Wolchok J.D. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24(21):4582-4585. doi:S0264-410X(05)00824-8 [pii] 10.1016/j.vaccine.2005.08.027.
5. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(10):4285-4289.
6. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421(6924):756-760.
7. Citri A., Gan J., Mosesson Y., Vereb G., Szollosi J., Yarden Y Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 2004, 5(12):1165-1170.
8. Clemente M., De Andres P.J., Pena L., Perez-Alenza M.D. Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy. Vet. Rec. 2009, 165(3):78-81. doi:165/3/78.[pii].
9. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6(4):443-446.
10. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., Dennis P.A., Lipkowitz S Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61(12):4892-4900.
11. DiMasi J.A., Grabowski H.G. Economics of new oncology drug development. J. Clin. Oncol. 2007, 25(2):209-216. doi:25/2/209 [pii] 10.1200/JCO.2006.09.0803.
12. Dutra A.P., Granja N.V., Schmitt F.C., Cassali G.D. c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz. J. Med. Biol. Res. 2004, 37(11):1673-1681.
13. Ferretti G., Felici A., Papaldo P., Fabi A., Cognetti F HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr. Opin. Obstet. Gynecol. 2007, 19(1):56-62.
14. Gama A., Gartner F., Alves A., Schmitt F. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res. Vet. Sci. 2009, 87(3):432-437.
15. Garnock-Jones K.P., Keating G.M., Scott L.J. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010, 70(2):215-239. doi:7 [pii] 10.2165/11203700-000000000-00000.
16. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., Oliviero B., Ballardini B., Da Prada G., Zambelli A., Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10(17):5650-5655.
17. Gish W., States D.J. Identification of protein coding regions by database similarity search. Nat. Genet. 1993, 3(3):266-272. 10.1038/ng0393-266.
18. Gordon I., Paoloni M., Mazcko C., Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009, 6(10):e1000161.
19. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22(6):1301-1309. doi:JVIM190 [pii] 10.1111/j.1939-1676.2008.0190.x.
20. Hudis CA Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357(1):39-51. doi:357/1/39 [pii] 10.1056/NEJMra043186.
21. Joy F., Basak S., Gupta S.K., Das P.J., Ghosh S.K., Ghosh T.C. Compositional correlations in canine genome reflects similarity with human genes. J. Biochem. Mol. Biol. 2006, 39(3):240-246.
22. Karagiannis P., Singer J., Hunt J., Gan S.K., Rudman S.M., Mechtcheriakova D., Knittelfelder R., Daniels T.R., Hobson P.S., Beavil A.J., Spicer J., Nestle F.O., Penichet M.L., Gould H.J., Jensen-Jarolim E., Karagiannis S.N. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 2009, 58(6):915-930.
23. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., Touge H., Makino H., Takata M., Miyata M., Nakamoto M., Burioka N., Shimizu E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 2007, 13(5):1552-1561.
24. Laskowski R.A., Moss M.M., Thornton JM D.S. ProCheck: a programm to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993, 26:283-291.
25. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7(4):301-311.
26. Lindblad-Toh K., Wade C.M., Mikkelsen T.S., Karlsson E.K., Jaffe D.B., Kamal M., Clamp M., Chang J.L., Kulbokas E.J., Zody M.C., Mauceli E., Xie X., Breen M., Wayne R.K., Ostrander E.A., Ponting C.P., Galibert F., Smith D.R., DeJong P.J., Kirkness E., Alvarez P., Biagi T., Brockman W., Butler J., Chin C.W., Cook A., Cuff J., Daly M.J., DeCaprio D., Gnerre S., Grabherr M., Kellis M., Kleber M., Bardeleben C., Goodstadt L., Heger A., Hitte C., Kim L., Koepfli K.P., Parker H.G., Pollinger J.P., Searle S.M., Sutter N.B., Thomas R., Webber C., Baldwin J., Abebe A., Abouelleil A., Aftuck L., Ait-Zahra M., Aldredge T., Allen N., An P., Anderson S., Antoine C., Arachchi H., Aslam A., Ayotte L., Bachantsang P., Barry A., Bayul T., Benamara M., Berlin A., Bessette D., Blitshteyn B., Bloom T., Blye J., Boguslavskiy L., Bonnet C., Boukhgalter B., Brown A., Cahill P., Calixte N., Camarata J., Cheshatsang Y., Chu J., Citroen M., Collymore A., Cooke P., Dawoe T., Daza R., Decktor K., DeGray S., Dhargay N., Dooley K., Dooley K., Dorje P., Dorjee K., Dorris L., Duffey N., Dupes A., Egbiremolen O., Elong R., Falk J., Farina A., Faro S., Ferguson D., Ferreira P., Fisher S., FitzGerald M., Foley K., Foley C., Franke A., Friedrich D., Gage D., Garber M., Gearin G., Giannoukos G., Goode T., Goyette A., Graham J., Grandbois E., Gyaltsen K., Hafez N., Hagopian D., Hagos B., Hall J., Healy C., Hegarty R., Honan T., Horn A., Houde N., Hughes L., Hunnicutt L., Husby M., Jester B., Jones C., Kamat A., Kanga B., Kells C., Khazanovich D., Kieu A.C., Kisner P., Kumar M., Lance K., Landers T., Lara M., Lee W., Leger J.P., Lennon N., Leuper L., LeVine S., Liu J., Liu X., Lokyitsang Y., Lokyitsang T., Lui A., Macdonald J., Major J., Marabella R., Maru K., Matthews C., McDonough S., Mehta T., Meldrim J., Melnikov A., Meneus L., Mihalev A., Mihova T., Miller K., Mittelman R., Mlenga V., Mulrain L., Munson G., Navidi A., Naylor J., Nguyen T., Nguyen N., Nguyen C., Nguyen T., Nicol R., Norbu N., Norbu C., Novod N., Nyima T., Olandt P., O'Neill B., O'Neill K., Osman S., Oyono L., Patti C., Perrin D., Phunkhang P., Pierre F., Priest M., Rachupka A., Raghuraman S., Rameau R., Ray V., Raymond C., Rege F., Rise C., Rogers J., Rogov P., Sahalie J., Settipalli S., Sharpe T., Shea T., Sheehan M., Sherpa N., Shi J., Shih D., Sloan J., Smith C., Sparrow T., Stalker J., Stange-Thomann N., Stavropoulos S., Stone C., Stone S., Sykes S., Tchuinga P., Tenzing P., Tesfaye S., Thoulutsang D., Thoulutsang Y., Topham K., Topping I., Tsamla T., Vassiliev H., Venkataraman V., Vo A., Wangchuk T., Wangdi T., Weiand M., Wilkinson J., Wilson A., Yadav S., Yang S., Yang X., Young G., Yu Q., Zainoun J., Zembek L., Zimmer A., Lander E.S. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438(7069):803-819.
27. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15(11):3856-3865. doi:1078-0432.CCR-08-1860 [pii] 10.1158/1078-0432.CCR-08-1860.
28. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77(6):400-410.
29. Martin de las Mulas J., Ordas J., Millan Y., Fernandez-Soria V., Ramon y Cajal S. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res. Treat. 2003, 80(3):363-367.
30. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29:291-325. doi:29/1/291 [pii] 10.1146/annurev.biophys.29.1.291.
31. Mayfield S., Vaughn J.P., Kute T.E. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res. Treat. 2001, 70(2):123-129.
32. Melo F., Sali A. Fold assessment for comparative protein structure modeling. Protein Sci. 2007, 16(11):2412-2426. doi:ps.072895107 [pii] 10.1110/ps.072895107.
33. Monne M., Hermansson M., von Heijne G A turn propensity scale for transmembrane helices. J. Mol. Biol. 1999, 288(1):141-145. doi:S0022-2836(99)92657-8 [pii] 10.1006/jmbi.1999.2657.
34. Mulligan R.M. Mammary cancer in the dog: a study of 120 cases. Am. J. Vet. Res. 1975, 36(9):1391-1396.
35. Nakashima H., Nishikawa K., Ooi T. The folding type of a protein is relevant to the amino acid composition. J. Biochem. 1986, 99(1):153-162.
36. Nestor M. Effect of cetuximab treatment in squamous cell carcinomas. Tumour Biol. 2010, 31(2):141-147. 10.1007/s13277-010-0018-8.
37. Owen L.N. A comparative study of canine and human breast cancer. Invest. Cell Pathol. 1979, 2(4):257-275.
38. Paik S., Hazan R., Fisher E.R., Sass R.E., Fisher B., Redmond C., Schlessinger J., Lippman M.E., King C.R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 1990, 8(1):103-112.
39. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8(2):147-156.
40. Patel D., Bassi R., Hooper A., Prewett M., Hicklin D.J., Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int. J. Oncol. 2009, 34(1):25-32.
41. Perez Alenza M.D., Pena L., del Castillo N., Nieto A.I. Factors influencing the incidence and prognosis of canine mammary tumours. J. Small Anim. Pract. 2000, 41(7):287-291.
42. Peruzzi D., Mesiti G., Ciliberto G., La Monica N., Aurisicchio L Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010, 28(5):1201-1208. doi:S0264-410X(09)01806-4 [pii] 10.1016/j.vaccine.2009.11.031.
43. Raben D., Helfrich B., Chan D.C., Ciardiello F., Zhao L., Franklin W., Baron A.E., Zeng C., Johnson T.K., Bunn P.A. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 2005, 11(2 Pt 1):795-805. doi:11/2/795 [pii].
44. Reis-Filho J.S., Milanezi F., Carvalho S., Simpson P.T., Steele D., Savage K., Lambros M.B., Pereira E.M., Nesland J.M., Lakhani S.R., Schmitt F.C. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005, 7(6):R1028-R1035. doi:bcr1341 [pii] 10.1186/bcr1341.
45. Rimawi M.F., Shetty P.B., Weiss H.L., Schiff R., Osborne C.K., Chamness G.C., Elledge R.M. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010, 116(5):1234-1242. doi:10.1002/cncr.24816.
46. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234(3):779-815. doi:S0022-2836(83)71626-8 [pii] 10.1006/jmbi.1993.1626.
47. Shen M.Y., Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 2006, 15(11):2507-2524. doi:15/11/2507 [pii] 10.1110/ps.062416606.
48. Singer C.F., Kostler W.J., Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim. Biophys. Acta 2008, 1786(2):105-113. doi:S0304-419X(08)00006-1 [pii] 10.1016/j.bbcan.2008.02.003.
49. Sorenmo K. Canine mammary gland tumors. Vet. Clin. North Am. Small Anim. Pract. 2003, 33(3):573-596.
50. Uva P., Aurisicchio L., Watters J., Loboda A., Kulkarni A., Castle J., Palombo F., Viti V., Mesiti G., Zappulli V., Marconato L., Abramo F., Ciliberto G., Lahm A., La Monica N., de Rinaldis E. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009, 10:135.
51. Vascellari M., Baioni E., Ru G., Carminato A., Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet. Res. 2009, 5:39.
52. Vincenzi B., Schiavon G., Silletta M., Santini D., Tonini G The biological properties of cetuximab. Crit. Rev. Oncol. Hematol. 2008, 68(2):93-106. doi:S1040-8428(08)00146-7 [pii].10.1016/j.critrevonc.2008.07.006.
53. Vincenzi B., Zoccoli A., Pantano F., Venditti O., Galluzzo S. Cetuximab: from bench to bedside. Curr. Cancer Drug Targets 2010, 10(1):80-95. doi:EPub-Abstract-CCDT-12 [pii].
54. Wallmann J., Epstein M.M., Singh P., Brunner R., Szalai K., El-Housseiny L., Pali-Scholl I., Jensen-Jarolim E. Mimotope vaccination for therapy of allergic asthma: anti-inflammatory effects in a mouse model. Clin. Exp. Allergy 2010, 40(4):650-658. doi:CEA3392 [pii] 10.1111/j.1365-2222.2009.03392.x.
55. Wallner B., Elofsson A. Can correct protein models be identified?. Protein Sci. 2003, 12(5):1073-1086. doi:10.1110/ps.0236803.